XML 33 R21.htm IDEA: XBRL DOCUMENT
v3.21.1

Revenue (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2021
Revenue from Contract with Customer [Abstract] |
Schedule of disaggregation of revenue | The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
| Three Months Ended March 31, |  |
| 2021 |  | 2020 |  |  |  |
Net product revenue | $ | 6,320.0 |  |  | $ | 5,403.5 |  |  |  |  |
Collaboration and other revenue (1) | 485.6 |  |  | 456.3 |  |  |  |  |
Revenue | $ | 6,805.6 |  |  | $ | 5,859.8 |  |  |  |  |
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $43.0 million and $35.4 million during the three months ended March 31, 2021 and 2020, respectively. The following table summarizes revenue by product for the three months ended March 31, 2021 and 2020:
| Three Months Ended March 31,
| 2021 |  | 2020
| U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total
Revenue—to unaffiliated customers: |  |  |  |  |  |  |
Diabetes: |  |  |  |  |  |  |
Trulicity® | $ | 1,116.8 |  | $ | 335.7 |  | $ | 1,452.4 |  |  | $ | 929.5 |  | $ | 299.9 |  | $ | 1,229.4 |
Humalog® (1) | 332.7 |  | 284.4 |  | 617.0 |  |  | 398.6 |  | 297.2 |  | 695.8 |
Humulin® | 219.0 |  | 102.7 |  | 321.7 |  |  | 214.1 |  | 101.5 |  | 315.7 |
Jardiance (2) | 151.2 |  | 160.8 |  | 312.0 |  |  | 144.6 |  | 122.9 |  | 267.5 |
Basaglar® | 175.2 |  | 71.4 |  | 246.6 |  |  | 230.4 |  | 73.3 |  | 303.7 |
Other Diabetes | 66.3 |  | 94.9 |  | 161.4 |  |  | 74.0 |  | 82.9 |  | 156.8 |
Total Diabetes | 2,061.2 |  | 1,049.9 |  | 3,111.1 |  |  | 1,991.2 |  | 977.7 |  | 2,968.9 |
Oncology: |  |  |  |  |  |  |
Alimta® | 261.1 |  | 297.8 |  | 559.0 |  |  | 324.2 |  | 235.8 |  | 560.1 |
Verzenio® | 172.8 |  | 96.2 |  | 269.0 |  |  | 129.4 |  | 58.6 |  | 188.0 |
Cyramza® | 80.2 |  | 160.3 |  | 240.5 |  |  | 89.1 |  | 149.9 |  | 239.0 |
Erbitux® | 107.9 |  | 14.4 |  | 122.4 |  |  | 117.8 |  | 13.0 |  | 130.8 |
Tyvyt® | — |  | 109.7 |  | 109.7 |  |  | — |  | 57.4 |  | 57.4 |
Other Oncology | 20.5 |  | 51.3 |  | 71.6 |  |  | (2.6) |  | 28.9 |  | 26.2 |
Total Oncology | 642.5 |  | 729.7 |  | 1,372.2 |  |  | 657.9 |  | 543.6 |  | 1,201.5 |
Immunology: |  |  |  |  |  |  |
Taltz® | 249.6 |  | 153.6 |  | 403.2 |  |  | 327.5 |  | 116.0 |  | 443.5 |
Olumiant® | 24.7 |  | 169.1 |  | 193.8 |  |  | 11.3 |  | 128.4 |  | 139.7 |
Other Immunology | 10.5 |  | 6.4 |  | 16.9 |  |  | 2.6 |  | — |  | 2.6 |
Total Immunology | 284.8 |  | 329.1 |  | 613.9 |  |  | 341.4 |  | 244.4 |  | 585.8 |
Neuroscience: |  |  |  |  |  |  |
Cymbalta® | 11.0 |  | 165.7 |  | 176.6 |  |  | 11.6 |  | 198.8 |  | 210.4 |
Emgality® | 101.5 |  | 18.0 |  | 119.5 |  |  | 67.3 |  | 6.7 |  | 74.0 |
Zyprexa® | 6.9 |  | 88.9 |  | 95.8 |  |  | 11.2 |  | 87.2 |  | 98.4 |
Other Neuroscience | 22.3 |  | 51.1 |  | 73.5 |  |  | 20.2 |  | 60.5 |  | 80.7 |
Total Neuroscience | 141.7 |  | 323.7 |  | 465.4 |  |  | 110.3 |  | 353.2 |  | 463.5 |
Other: |  |  |  |  |  |  |
COVID-19 Antibodies (3) | 650.6 |  | 159.5 |  | 810.1 |  |  | — |  | — |  | — |
Forteo® | 97.7 |  | 100.8 |  | 198.5 |  |  | 122.5 |  | 149.8 |  | 272.4 |
Cialis® | 8.6 |  | 118.1 |  | 126.8 |  |  | 26.1 |  | 167.0 |  | 193.0 |
Other | 54.2 |  | 53.4 |  | 107.5 |  |  | 79.4 |  | 95.3 |  | 174.7 |
Total Other | 811.1 |  | 431.8 |  | 1,242.9 |  |  | 228.0 |  | 412.1 |  | 640.1 |
Revenue | $ | 3,941.3 |  | $ | 2,864.3 |  | $ | 6,805.6 |  |  | $ | 3,328.8 |  | $ | 2,531.0 |  | $ | 5,859.8 |
Numbers may not add due to rounding. (1) Humalog revenue includes insulin lispro. (2) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR. (3) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations (EUAs). The following table summarizes revenue by geographical area:
| Three Months Ended March 31, |  |
| 2021 |  | 2020 |  |  |  |
Revenue—to unaffiliated customers (1): |  |  |  |  |  |  |
U.S. | $ | 3,941.3 |  |  | $ | 3,328.8 |  |  |  |  |
Europe | 1,321.2 |  |  | 1,061.0 |  |  |  |  |
Japan | 571.8 |  |  | 592.3 |  |  |  |  |
China | 362.2 |  |  | 267.3 |  |  |  |  |
Other foreign countries | 609.1 |  |  | 610.4 |  |  |  |  |
Revenue | $ | 6,805.6 |  |  | $ | 5,859.8 |  |  |  |  |
Numbers may not add due to rounding. (1) Revenue is attributed to the countries based on the location of the customer.
Schedule of amounts recorded for contract liabilities | The following table summarizes contract liability balances:
| March 31, 2021 |  | December 31, 2020
Contract liabilities | $ | 346.6 |  |  | $ | 276.8 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration